American Association for Cancer Research
Browse
23266066cir150065-sup-146481_1_supp_3021127_nq1480_eps_zip.zip (128.2 kB)

Supplementary Figure 3 from Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer

Download (128.2 kB)
software
posted on 2023-04-03, 23:00 authored by Jai Rautela, Nikola Baschuk, Clare Y. Slaney, Krishnath M. Jayatilleke, Kun Xiao, Bradley N. Bidwell, Erin C. Lucas, Edwin D. Hawkins, Peter Lock, Christina S. Wong, Weisan Chen, Robin L. Anderson, Paul J. Hertzog, Daniel M. Andrews, Andreas Möller, Belinda S. Parker

Immune suppressor cell and T lymphocyte accumulation in the peripheral blood of WT and Ifnar1-/- mice.

History

ARTICLE ABSTRACT

Metastatic progression is the major cause of breast cancer–related mortality. By examining multiple syngeneic preclinical breast cancer models in mice lacking a functional type-I interferon receptor (Ifnar1−/− mice), we show that host-derived type-I interferon (IFN) signaling is a critical determinant of metastatic spread that is independent of primary tumor growth. In particular, we show that bone metastasis can be accelerated in Balb/c Ifnar1−/− mice bearing either 4T1 or 66cl4 orthotopic tumors and, for the first time, present data showing the development of bone metastasis in the C57Bl/6 spontaneous MMTV-PyMT–driven model of tumorigenesis. Further exploration of these results revealed that endogenous type-I IFN signaling to the host hematopoietic system is a key determinant of metastasis-free survival and critical to the responsiveness of the circulating natural killer (NK)–cell population. We find that in vivo–stimulated NK cells derived from wild-type, but not Ifnar1−/−, mice can eliminate the 4T1 and 66cl4 breast tumor lines with varying kinetics in vitro. Together, this study indicates that the dysregulated immunity resulting from a loss of host type-I IFN signaling is sufficient to drive metastasis, and provides a rationale for targeting the endogenous type-I IFN pathway as an antimetastatic strategy. Cancer Immunol Res; 3(11); 1207–17. ©2015 AACR.